The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
DKK 2016 | Prolonging remission and survival in multiple myeloma
Christof Scheid
• 25 Feb 2016
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD, from University of Cologne, Cologne, Germany, evaluates current and emerging approaches for managing patients with multiple myeloma, including drug sequencing and a clinical trial investigating lenalidomide, bortezomib, dexamethasone and elotuzumab as induction therapy for newly diagnosed patients.
